560 related articles for article (PubMed ID: 14518186)
1. [Myelofibrosis in patients with chronic myeloid leukemia treated with interferon-alpha].
Kumas Sotiris ; Semenova EA; Turkina AG; Zakharova AV; Domracheva EV; Khoroshko ND; Frank GA
Arkh Patol; 2003; 65(4):9-12. PubMed ID: 14518186
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Bueso-Ramos CE; Cortes J; Talpaz M; O'Brien S; Giles F; Rios MB; Medeiros LJ; Kantarjian H
Cancer; 2004 Jul; 101(2):332-6. PubMed ID: 15241831
[TBL] [Abstract][Full Text] [Related]
3. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
[TBL] [Abstract][Full Text] [Related]
4. Evolution of bone marrow fibrosis and stromal antigenic expression in chronic myeloid leukemia on alpha interferon and Ara-C therapy.
Straetmans N; Ma DD; Nevell DF; Arthur C
Hematopathol Mol Hematol; 1996; 10(4):213-22. PubMed ID: 9042664
[TBL] [Abstract][Full Text] [Related]
5. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Buesche G; Ganser A; Schlegelberger B; von Neuhoff N; Gadzicki D; Hecker H; Bock O; Frye B; Kreipe H
Leukemia; 2007 Dec; 21(12):2420-7. PubMed ID: 17805334
[TBL] [Abstract][Full Text] [Related]
6. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
Takahari D; Matsunaga T; Fujimi A; Kikuchi T; Seki R; Tanaka I; Takemoto N; Akiyama T; Sato T; Terui T; Kogawa K; Kato J; Kura T; Maeda T; Niitsu Y
Rinsho Ketsueki; 2002 Oct; 43(10):924-30. PubMed ID: 12462028
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related changes of CD20+ and CD45RO+ lymphocyte subsets in chronic myeloid leukemia (CML): an immunohistochemical and morphometric study on sequential trephine biopsies of the bone marrow.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Cvetanovska G; Blum N; Schaefer HE
Mod Pathol; 2000 Aug; 13(8):888-96. PubMed ID: 10955456
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of chronic myeloid leukemia with interferon-alpha].
Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H
Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958
[TBL] [Abstract][Full Text] [Related]
10. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Kantarjian HM; Bueso-Ramos CE; Talpaz M; O'Brien S; Giles F; Faderl S; Wierda W; Rios MB; Shan J; Cortes J
Cancer; 2005 Aug; 104(4):777-80. PubMed ID: 15971197
[TBL] [Abstract][Full Text] [Related]
11. Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia.
Buesche G; Freund M; Hehlmann R; Georgii A; Ganser A; Hecker H; Heimpel H; Fonatsch C; Heinze B; Pfirrmann M; Holgado S; Schmeil A; Tobler A; Hasford J; Buhr T; Kreipe HH;
Leukemia; 2004 Sep; 18(9):1460-7. PubMed ID: 15284854
[TBL] [Abstract][Full Text] [Related]
12. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
13. Incidence of Myelofibrosis in Chronic Myeloid Leukemia, Multiple Myeloma, and Chronic Lymphoid Leukemia during Various Phases of Diseases.
Dolgikh TY; Domnikova NP; Tornuev YV; Vinogradova EV; Krinitsyna YM
Bull Exp Biol Med; 2017 Feb; 162(4):483-487. PubMed ID: 28239786
[TBL] [Abstract][Full Text] [Related]
14. [Pathological characteristics of leukemia patients with secondary myelofibrosis and their relationship with the prognosis of disease].
Guan JH; Wang XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):311-4. PubMed ID: 23628022
[TBL] [Abstract][Full Text] [Related]
15. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
16. Cellular composition and reticulin fibrosis in chronic myeloid leukaemia.
Ghosh K; Varma N; Varma S; Dash S
Indian J Cancer; 1988 Sep; 25(3):128-35. PubMed ID: 3224984
[No Abstract] [Full Text] [Related]
17. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
18. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
[TBL] [Abstract][Full Text] [Related]
19. [Successful low-dose etoposide therapy for a case of myelofibrosis with chronic myelogenous leukemia megakaryocytic predominance type].
Katayama T; Masuoka H; Yoshida M; Watanabe R; Nishiwaki K; Shimada T; Kaito K; Ochiai S; Kobayashi M; Sakai O
Rinsho Ketsueki; 1992 Apr; 33(4):488-93. PubMed ID: 1602613
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
